Stay updated on Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial
Sign up to get notified when there's something new on the Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial page.

Latest updates to the Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page footer now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe record for a recruiting Phase 2 study of neoadjuvant pembrolizumab and talimogene laherparepvec for Stage III melanoma is displayed, including eligibility criteria, study design and outcomes, and contact details.SummaryDifference44%

- Check22 days agoChange DetectedThe site footer now identifies the release as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check29 days agoChange DetectedA banner announces NIH website updates and says some content may use “Super Intelligence” (SI) instead of “Artificial Intelligence” (AI). It appears above the unchanged 403 error page.SummaryDifference1%

- Check36 days agoChange DetectedThe footer’s site revision identifier advanced from v3.7.1 to v3.7.2, while the page still shows a 403 error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1 on the 403 page.SummaryDifference0.2%

Stay in the know with updates to Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial page.